Nykode Therapeutics ASA
OSE:NYKD
to continue NYKD research
to continue NYKD research
You've reached your weekly stock limit.
Sign UpNykode Therapeutics ASA?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.2745
9.9622
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
What unique competitive advantages
does Nykode Therapeutics ASA hold over its rivals?
What risks and challenges
does Nykode Therapeutics ASA face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Nykode Therapeutics ASA.
Provide an overview of the primary business activities
of Nykode Therapeutics ASA.
What unique competitive advantages
does Nykode Therapeutics ASA hold over its rivals?
What risks and challenges
does Nykode Therapeutics ASA face in the near future?
Summarize the latest earnings call
of Nykode Therapeutics ASA.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Nykode Therapeutics ASA.
Provide P/S
for Nykode Therapeutics ASA.
Provide P/E
for Nykode Therapeutics ASA.
Provide P/OCF
for Nykode Therapeutics ASA.
Provide P/FCFE
for Nykode Therapeutics ASA.
Provide P/B
for Nykode Therapeutics ASA.
Provide EV/S
for Nykode Therapeutics ASA.
Provide EV/GP
for Nykode Therapeutics ASA.
Provide EV/EBITDA
for Nykode Therapeutics ASA.
Provide EV/EBIT
for Nykode Therapeutics ASA.
Provide EV/OCF
for Nykode Therapeutics ASA.
Provide EV/FCFF
for Nykode Therapeutics ASA.
Provide EV/IC
for Nykode Therapeutics ASA.
Show me price targets
for Nykode Therapeutics ASA made by professional analysts.
What are the Revenue projections
for Nykode Therapeutics ASA?
How accurate were the past Revenue estimates
for Nykode Therapeutics ASA?
What are the Net Income projections
for Nykode Therapeutics ASA?
How accurate were the past Net Income estimates
for Nykode Therapeutics ASA?
What are the EPS projections
for Nykode Therapeutics ASA?
How accurate were the past EPS estimates
for Nykode Therapeutics ASA?
What are the EBIT projections
for Nykode Therapeutics ASA?
How accurate were the past EBIT estimates
for Nykode Therapeutics ASA?
Compare the revenue forecasts
for Nykode Therapeutics ASA with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Nykode Therapeutics ASA and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Nykode Therapeutics ASA against its competitors.
Analyze the profit margins
(gross, operating, and net) of Nykode Therapeutics ASA compared to its peers.
Compare the P/E ratios
of Nykode Therapeutics ASA against its peers.
Discuss the investment returns and shareholder value creation
comparing Nykode Therapeutics ASA with its peers.
Analyze the financial leverage
of Nykode Therapeutics ASA compared to its main competitors.
Show all profitability ratios
for Nykode Therapeutics ASA.
Provide ROE
for Nykode Therapeutics ASA.
Provide ROA
for Nykode Therapeutics ASA.
Provide ROIC
for Nykode Therapeutics ASA.
Provide ROCE
for Nykode Therapeutics ASA.
Provide Gross Margin
for Nykode Therapeutics ASA.
Provide Operating Margin
for Nykode Therapeutics ASA.
Provide Net Margin
for Nykode Therapeutics ASA.
Provide FCF Margin
for Nykode Therapeutics ASA.
Show all solvency ratios
for Nykode Therapeutics ASA.
Provide D/E Ratio
for Nykode Therapeutics ASA.
Provide D/A Ratio
for Nykode Therapeutics ASA.
Provide Interest Coverage Ratio
for Nykode Therapeutics ASA.
Provide Altman Z-Score Ratio
for Nykode Therapeutics ASA.
Provide Quick Ratio
for Nykode Therapeutics ASA.
Provide Current Ratio
for Nykode Therapeutics ASA.
Provide Cash Ratio
for Nykode Therapeutics ASA.
What is the historical Revenue growth
over the last 5 years for Nykode Therapeutics ASA?
What is the historical Net Income growth
over the last 5 years for Nykode Therapeutics ASA?
What is the current Free Cash Flow
of Nykode Therapeutics ASA?
Discuss the annual earnings per share (EPS)
trend over the past five years for Nykode Therapeutics ASA.
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
NO |
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
602.8m NOK | 0 | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
334.3B USD | 9.7 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
160.4B USD | 9.4 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
139.1B USD | 6.8 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD | 11.7 |
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 768.2 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
117.5B AUD | 10.8 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.2B USD | 4.4 |
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.3B USD | 20.6 |
|
NO |
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Average EV/GP:
318.6
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
Not Available |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
9.7
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
9.4
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
6.8
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
11.7
|
|
US |
E
|
Epizyme Inc
F:EPE
|
2 768.2
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
10.8
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
4.4
|
|
US |
S
|
Seagen Inc
F:SGT
|
26
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
20.6
|
|
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.